KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumor...
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
cutting-edge, multi-mechanistic oncolytic immunotherapies, today announced a clinical trial collaboration and supply agreement with Roche to evaluate VET3-TGI, a novel oncolytic immunotherapy developed using KaliVir's proprietary Vaccinia Enhanced Template (VET™) platform, in combination with Roche's atezolizumab (Tecentriq®). The collaboration will support the expansion of KaliVir's ongoing STEALTH-001 (NCT06444815) Phase 1a/1b clinical study evaluating VET3-TGI in patients with advanced or metastatic solid tumors. Under the terms of the agreement, Roche will supply atezolizumab for use in combination with VET3-TGI across multiple dosing cohorts. VET3-TGI is KaliVir's lead oncolytic immunotherapy candidate, designed to directly destroy tumor cells while activating a potent immune response through a proprietary payload that includes interleukin-12 (IL-12) and a TGF-ß inhibitor. Combining VET3-TGI with atezolizumab aims to amplify immune activation and reshape the tumor microenviro
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche (OTCMKTS:RHHBY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis) [Yahoo! Finance]Yahoo! Finance
- Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]Yahoo! Finance
- Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer SymposiumBusiness Wire
- Roche shares hit milestone with 19% November surge on breast cancer and promising MS drug trials [Seeking Alpha]Seeking Alpha